TLR4 and infection: These results demonstrate that a subunit vaccine consisting of Wuhan-Hu-1 spike protein adjuvanted with an emulsion can provide protection from a lethal infection by the highly mutated variant XBB.1, and that the addition of a synthetic TLR4 agonist, INI-2002, can significantly enhance disease resistance.